Literature DB >> 16200083

Tuberculosis control in the era of HIV.

Paul Nunn1, Brian Williams, Katherine Floyd, Christopher Dye, Gijs Elzinga, Mario Raviglione.   

Abstract

Without HIV, the tuberculosis (TB) epidemic would now be in decline almost everywhere. However, instead of looking forward to the demise of TB, countries that are badly affected by HIV are struggling against a rising tide of HIV-infected patients with TB. As a consequence, global TB control policies have had to be revised and control of TB now demands increased investment. This paper assesses what is being done to address the issue and what remains to be done.

Entities:  

Mesh:

Year:  2005        PMID: 16200083     DOI: 10.1038/nri1704

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  63 in total

1.  Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.

Authors:  Ted Cohen; Marc Lipsitch; Rochelle P Walensky; Megan Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  Rv1675c (cmr) regulates intramacrophage and cyclic AMP-induced gene expression in Mycobacterium tuberculosis-complex mycobacteria.

Authors:  Michaela A Gazdik; Guangchun Bai; Yan Wu; Kathleen A McDonough
Journal:  Mol Microbiol       Date:  2008-11-14       Impact factor: 3.501

3.  New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya.

Authors:  John Mansoer; Suzanne Scheele; Katherine Floyd; Christopher Dye; Joseph Sitienei; Brian Williams
Journal:  Bull World Health Organ       Date:  2009-03       Impact factor: 9.408

4.  Expression, purification and preliminary crystallographic analysis of N-acetylglucosamine-1-phosphate uridylyltransferase from Mycobacterium tuberculosis.

Authors:  Jiang Yin; Craig R Garen; Maia M Cherney; Leonid T Cherney; Michael N G James
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-08-09

5.  Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine.

Authors:  Chethan Bachireddy; Michael C Soule; Jacob M Izenberg; Sergey Dvoryak; Konstantin Dumchev; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

6.  The relationship between inflammatory marker levels and pulmonary tuberculosis severity.

Authors:  Ozlem Abakay; Abdurrahman Abakay; Hadice Selimoglu Sen; Abdullah C Tanrikulu
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

7.  Crystallization and preliminary X-ray characterization of the glpX-encoded class II fructose-1,6-bisphosphatase from Mycobacterium tuberculosis.

Authors:  Hiten J Gutka; Scott G Franzblau; Farahnaz Movahedzadeh; Cele Abad-Zapatero
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-05-26

8.  Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation.

Authors:  Eliseo F Castillo; Alexander Dekonenko; John Arko-Mensah; Michael A Mandell; Nicolas Dupont; Shanya Jiang; Monica Delgado-Vargas; Graham S Timmins; Dhruva Bhattacharya; Hongliang Yang; Julie Hutt; C Rick Lyons; Karen M Dobos; Vojo Deretic
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-23       Impact factor: 11.205

9.  Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection.

Authors:  Anthony A Ryan; Joanne M Spratt; Warwick J Britton; James A Triccas
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

10.  Potent immune responses of Ag-specific Vgamma2Vdelta2+ T cells and CD8+ T cells associated with latent stage of Mycobacterium tuberculosis coinfection in HIV-1-infected humans.

Authors:  Lingyun Shao; Wenhong Zhang; Shu Zhang; Crystal Y Chen; Weimin Jiang; Yunya Xu; Chengyan Meng; Xinhua Weng; Zheng W Chen
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.